We consistently found an increased reporting of pneumonitis toxicity for anti-PD-1/CTLA-4 plus chemotherapy compared with other anti-PD-1/CTLA-4 regimes in the two pharmacovigilance databases. This evidence concerns the gene PDCD1 and pneumonitis.